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Abstract
Background: Annually, around 7.9 million children are born with birth defects and the contribution of congenital
malformations to neonatal mortality is generally high. Congenital malformations in children born to mothers with
hypertensive disorders during pregnancy has marginally been explored.
Methods: Country incidence of congenital malformations was estimated using data on the 310 401 livebirths of
the WHO Multicountry Survey which reported information from 359 facilities across 29 countries. A random-effect
logistic regression model was utilized to explore the associations between six broad categories of congenital
malformations and the four maternal hypertensive disorders “Chronic Hypertension”, “Preeclampsia” and “Eclampsia”
and “Chronic hypertension with superimposed preeclampsia”.
Results: The occupied territories of Palestine presented the highest rates in all groups of malformation except for
the “Lip/Cleft/Palate” category. Newborns of women with chronic maternal hypertension were associated with a 3.7
(95 % CI 1.3–10.7), 3.9 (95 % CI 1.7–9.0) and 4.2 (95 % CI 1.5–11.6) times increase in odds of renal, limb and lip/cleft/
palate malformations respectively. Chronic hypertension with superimposed preeclampsia was associated with a 4.3
(95 % CI 1.3–14.4), 8.7 (95 % CI 2.5–30.2), 7.1 (95 % CI 2.1–23.5) and 8.2 (95 % CI 2.0–34.3) times increase in odds of
neural tube/central nervous system, renal, limb and Lip/Cleft/Palate malformations.
Conclusions: This study shows that chronic hypertension in the maternal period exposes newborns to a significant
risk of developing renal, limb and lip/cleft/palate congenital malformations, and the risk is further exacerbate by
superimposing eclampsia. Additional research is needed to identify shared pathways of maternal hypertensive
disorders and congenital malformations.
Background
Annually, around 7.9 million children are born with birth de-
fects [1]. At least 3.3 million children under 5 years of age
die from birth defects every year and an estimated 3.2 million
of those who survive may be disabled for life [1]. The contri-
bution of congenital malformations to neonatal mortality is
generally higher, in lower infant mortality countries [1].
Eclampsia/pre-eclampsia syndrome consists of a state
of excessive systemic inflammation causing new-onset
proteinuria and hypertension during the second half of
pregnancy [2]. Pre-eclampsia affects between two and
eight percent [3–7] of all pregnancies with a worldwide
estimation of 8 370 000 cases per year whilst eclampsia
ranges from 0.3 to 1.4 % [6, 7]. The syndrome affects
both the mother and her fetus and the pathogenesis fea-
tures an impaired placental perfusion and widespread
endothelial cell dysfunction [8, 9]. Severe pre-eclampsia
is a major cause of severe maternal/fetal morbidity and
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adverse perinatal outcomes, such as prematurity and
intrauterine growth restriction [10].
Only a few studies have explored the associations be-
tween pre-eclampsia and malformations providing in-
conclusive results: one reported an increased risk of
renal dysgenesis (OR 4.7, 95 % CI 1.7–12.8), esophageal
atresia/stenosis (OR 4.6, 95 % CI 1.8–12.2) and rectal/
anal stenosis (OR 3.7, 95 % CI 1.6–8.5) in the offspring
of pregnant women who developed preeclampsia with
superimposed chronic hypertension [11] whilst another
found that esophageal atresia/stenosis was a greater risk
in pregnant women with chronic hypertension (OR 3.1,
95 % CI 1.4–6.8) [12]. Some studies have suggested a
correlation between maternal hypertension and severe
hypospadias (OR 2.1, 95 % CI 1.6–2.9) [13, 14]. Altered
perfusion of placenta and embryo/fetus is being consid-
ered as plausible biological pathway [15]; however, there
is a dearth of knowledge on the likely common events
leading to hypertensive disorders and congenital abnor-
malities [16] mainly because of the different gestational
timing of these two separate events, namely first trimes-
ter of gestation for congenital malformation and second/
third trimester for hypertensive disorders [17]. Using data
collected in 29 countries worldwide as part of the World
Health Organization Multicountry Survey (WHOMCS),
in this analysis we aimed to examine the association be-
tween hypertensive disorders of pregnancy and the risk of
congenital malformations in the newborn.
Methods
Settings and participants
The study population and data collection methods used
in this survey are described in detailed elsewhere [18]. In
brief, the WHOMCS was an international, multi-
country, cross-sectional survey for all delivering mothers
and their newborns in 359 facilities across 29 countries
involving over 1500 collaborators. It was conducted from
May 2010 to December 2011 and captured data from
over 314 000 deliveries.
The Study involved five WHO regions: African Region
(Angola, DR Congo, Kenya, Niger, Nigeria and Uganda);
Region of the Americas (Argentina, Brazil, Ecuador,
Mexico, Nicaragua, Paraguay and Peru); Eastern Medi-
terranean Region (Afghanistan, Jordan, Lebanon, occu-
pied Palestinian territory, Palestine, Pakistan and Qatar);
South-East Asia Region (India, Nepal, Sri Lanka and
Thailand); Western Pacific Region (Cambodia, China,
Japan, Mongolia, Philippines and Vietnam).
The hospitals with a minimum of 1000 deliveries per
year were identified. Within each country, the capital
city was included, along with two randomly selected
provinces with probability proportional to their popula-
tion size. In each province and in the capital city, seven
hospitals with over 1000 deliveries per year and the
capacity to perform caesarean sections were selected
using a multi-stage cluster sampling method.
Participants in the study were all women giving birth
during the data collection period in the participating
hospitals together with their respective newborns, all
maternal near-miss cases and all maternal deaths taking
place in the participating hospitals up to seven postpar-
tum/postabortion days, discharge or death (whichever
came first), regardless of the gestational age and delivery
status.
Data were collected from hospital medical records
through daily visits to the obstetrical/postpartum ward,
gynecologic/abortion care unit, delivery room and inten-
sive care unit for the duration of 2 months if the hospital
had 6000 deliveries/year or and three months if the
health facility had less than 6000 deliveries/year [19].
Study population
In the WHOMCS, ascertainment of malformations was
made by obstetricians and pediatrician and the inclusion
criteria were major congenital anomalies among live
births and stillbirths.
All live births (n = 310 401) during the data collection
were included to explore the frequency of congenital
malformation.
We aimed to evaluate the risk of specific categories of
congenital malformation against maternal hypertensive
disorders. Multiple pregnancies were excluded from the
analysis since more susceptible to maternal complica-
tions, potentially distorting estimates. Also stillbirths
were excluded from the analysis, as our preliminary ana-
lysis indicated that congenital malformations were sig-
nificantly under-reported in stillbirths.
Mothers and newborns with missing information on
status at birth (n = 1426) or number of fetuses (n = 60)
were excluded. Individuals with missing values on con-
genital malformations (n = 20) and maternal hyperten-
sive disorders (n = 9) were also excluded in the analysis
leaving a final study population of 302 135 women. See
flowchart showing the selection of study participants in
Fig. 1.
Outcomes and exposures
In the WHOMCS, data collectors performed daily visits
to the obstetrical/postpartum ward, gynaecologic/abor-
tion care unit, delivery room and intensive care unit to
review medical records and extract data from these into
individual data forms.
Six categories of congenital malformations were de-
fined for data collector to extract data from the medical
records in line with the International Clearinghouse for
Birth Defects Monitoring Systems classification [20].
The six groups consisted of: “Neural tube/Central Ner-
vous System” (Anencephaly, Spina Bifida, Encephalocele,
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Microcephaly, Holoprosencephaly, Hydrocephaly, Anophthal-
mos/microphtalmos, Anotia/microtia) “Cardiac” (Trans-
position of great vessels, Tetralogy of Fallot, Hypoplastic
left Heart Syndrome, Coarctation of the aorta), “Renal”
(Renal agenesis, Cystic kidney, Bladder exstrophy), “Limb”
(Polydactyly, Limb reduction defects), “Lip/Cleft/Palate”
(Choanal atresia, Cleft palate without cleft lip, Cleft lip
with or without cleft palate) and “Chromosomal” (Tri-
somy 13, Trisomy 18, Down syndrome).
Hypertensive disorders information was collected from
delivery records and was categorized into “Chronic
Hypertension”, “Preeclampsia” and “Eclampsia”. The
study definition for pre-eclampsia was the presence of
hypertension (blood pressure >140/90 mmHg) associ-
ated with proteinuria in women known to be previously
normotensive. Eclampsia was defined as the occurrence
of convulsions and/or coma unrelated to other cerebral
conditions in women with signs and symptoms of pre-
eclampsia. Seizures are of grand mal type and may first
appear before labour, during labour or up to 48 h post-
partum. Chronic hypertension was defined as a blood
pressure >140/90 mmHg diagnosed prior to the onset of
pregnancy or before the 20th week of gestation; all women
with chronic hypertension and who developed preeclamp-
sia were grouped and classified under the new variable
“Chronic hypertension with superimposed preeclampsia”.
Statistical analysis
We determined the frequency of newborns with con-
genital malformations per 1000 live births for each of
the 29 countries participating in the WHOMCS strati-
fied by WHO Region and by Human Development Index
(HDI) [21]. Whereas the categorization by WHO regions
gives a geographical perspective, it can conceal import-
ant epidemiological differences and patterns. HDI is a
summary measure of human development. It measures
the average achievements in a country in three dimen-
sions of human development: a long and healthy life, ac-
cess to knowledge and a decent standard of living.
Categorization of countries by HDI is an increasingly
used approach as it pools together more similar coun-
tries [22, 23].
We used frequencies to describe the congenital mal-
formation categories by maternal age, marital status,
woman education and number of previous births; as
health facilities were the primary sampling unit of the
318 499 newborns in the WHOMCS dataset
310 401 live births 
No data on status at birth (n=1426) 
Fresh stillbirths (n= 4330)
Macerated stillbirths (n=2342)
302 164 live births single pregnancies 
No data on multiple pregnancies (n=60) 
Multiple pregnancies (n=8177)
No data on congenital malformation (n=20)
No data on hypertensive disorders (n=9)
302 135 live births analyzed for association between congenital 
malformations and hypertensive maternal disorders 
Fig. 1 Study population selection process
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WHOMCS, individual-level analyses may be affected by
clustering. After excluding missing data, all estimates of
association (chi-square tests) were corrected for the
cluster effects (health facilities as sampling units, coun-
tries as strata) and P < 0.05 was regarded as significant.
Crude and adjusted ORs with 95 % CI were evaluated
using a multi-category logistic regression models for the
occurrence of any congenital malformation; the adjusted
logistic regression model considered potential maternal
confounders: age, marital status, woman education and
number of previous births. Because of the possible clus-
ter effect of individual analysis [24] we generated the OR
adjusted for the random mixed effect of facilities nested
within countries and took into account the sampling se-
lection of the additional provinces into account. Consid-
ering the large variability of reporting amongst WHO
Regions and specifically the very low incidence of con-
genital malformation reported in the African Region par-
ticipating countries, we performed a sensitivity analysis
excluding the African Region countries.
Stata 13 was used for statistical analyses and p-values
<0.05 was regarded as significant.
The WHOMCS was approved by the WHO Ethical
Review Committee and the relevant ethical clearance
bodies in participating countries and facilities. Written
consent from individual participants was not required.
Results
In the WHOMCS, overall 1706 newborns with congeni-
tal malformations were recorded, distributed as follows:
322 (1.04 per 1000 livebirths) “Neural tube/Central Ner-
vous System”, 494 (1.59 per 1000 livebirths) “Cardiac”,
136 (0.44 per 1000 livebirths) “Renal”, 367 (1.18 per
1000 livebirths) “Limb”, 212 (0.68 per 1000 livebirths)
“Lip/Cleft/Palate” and 175 (0.56 per 1000 livebirths)
“Chromosomal”.
By country, the occupied territories of Palestine pre-
sented the highest rates in all malformation except for
“Lip/Cleft/Palate” where Japan was highest. In the occu-
pied territories of Palestine, it was found a prevalence of
10.2 cases of “Neural tube/Central Nervous System”,
24.6 cases of “Cardiac”, 11.3 cases for “Renal”, 8.2 cases
for “Limb” and 3.1 cases for “Chromosomal” (Table 1).
On the other hand, Niger reported only two cases of
“Limb”, with a total of 0.2 malformation per 1000 live
births.
When considering prevalence of congenital malforma-
tions by WHO Regions the highest prevalence of malfor-
mations as a whole was reported in the Region of the
Americas with 9.2 cases per 1000 live births and the
lowest in the African Region with 2.5 cases for 1000 live
births (Table 1).
The stratification by HDI showed a clear linear trend
as countries with high HDI and very high HDI had the
highest frequency of congenital malformations (11.4 per
1000 livebirths and 9.7 per 1000 livebirths respectively)
followed countries with medium HDI (4.3 per 1000 live-
births), and finally countries with low HDI (2.7 per 1000
livebirths) (Table 2).
We noted that “Chromosomal” malformations were
significantly higher with increasing maternal age and in-
creasing number of previous births; similarly “Cardiac”
malformations were significantly more common as ma-
ternal age and years of education increase (Table 3).
The study population included 1152 women with
chronic hypertension, 6163 women with preeclampsia,
765 women with eclampsia and 294 with preeclampsia
superimposed on chronic hypertension.
Some variability on reporting exposure data existed
across WHO regions: chronic hypertension incidence
ranged from 2.3 cases per 1000 livebirths in SEAR to 6.6
cases per 1000 livebirths in AMR; preeclampsia was the
lowest in EMR with 12.1 cases per 1000 livebirths and
highest in AMR with 38.2 cases per 1000 livebirths;
eclampsia varied from a low 1.2 cases per 1000 livebirths
in WPR to 5.0 cases each 1000 livebirths in AFR; finally
chronic hypertension with superimposed preeclampsia
ranged from 0.2 cases per 1000 livebirths in SEAR to 2.1
per 1000 livebirths in AMR.
Table 4 presents the crude and adjusted odd ratios for
the four the different categories of hypertensive disor-
ders of pregnancy and the different birth defects consid-
ered in this analysis.
When adjusted for covariates and for mixed effects at
country and hospital levels, we found that newborns of
women with chronic maternal hypertension are at higher
risk of renal (aOR 3.7, 95 % CI 1.3–10.7), limb (aOR 3.9,
95 % CI 1.7–9.0) and lip/cleft/palate malformations
(aOR 4.2, 95 % CI 1.5–11.6) while preeclampsia held sig-
nificant associations with “Cardiac” (aOR 2.3, 95 % CI
1.6–3.5). Eclampsia was not associated to the malforma-
tion for which data were available (Lip/Cleft/Palate).
The multivariable analysis strengthened the association
between the chronic hypertension with superimposed
preeclampsia and “neural tube/central nervous system”
(aOR 4.3, 95 % CI 1.3–14.4), “Renal” (aOR 8.7, 95 % CI
2.5–30.2), “Limb” (aOR 7.1, 95 % CI 2.1–23.5) and “Lip/
Cleft/Palate” (aOR 8.2, 95 % CI 2.0–34.3) malformations
(Table 4).
The sensitivity analysis carried without the African
countries showed no substantial differences on finding
with the original pooled analysis (Table 5).
Discussion
This multicountry, facility-based survey showed wide
differences in the prevalence and ascertainment of con-
genital abnormalities in facility deliveries across the 29
countries with occupied Palestinian territory the leading
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country for almost all defects such as “Cardiac” malforma-
tions with 24.6 cases per 1000 live births. Conversely some
African countries showed the lowest incidence rates like
Niger reporting overall only two “Limb” malformations
with an overall rate of 0.2 cases per 1000 live births
(Table 1). At aggregated level, the highest rates were ob-
served in the American Region and the lowest in Africa
Region. On the other hand, higher rates of birth defects
were seen in higher HDI countries showing a gradual de-
crease with lowering HDI. Interpretation of these patterns
needs caution as better screening for congenital malfor-
mations in countries with higher HDI is likely to be dir-
ectly related to higher resourced facilities which in turn
would explain higher identification and reporting rates in
these countries. We cannot rule out that this as a reason
for the lower rates in the African Region (0.25 %).
Table 1 The prevalence of newborn with congenital malformations by country per 1000 livebirths














AFR Angola 20 10 072 0 0 1 0.1 0 0 1 0.1 1 0.1 1 0.1 4 0.4
DR Congo 21 8 525 5 0.6 1 0.1 0 0 6 0.7 2 0.2 1 0.1 15 1.7
Kenya 20 20 057 30 1.5 6 0.3 2 0.1 55 2.7 18 0.9 11 0.5 122 6.1
Niger 11 10 714 0 0 0 0 0 0 2 0.2 0 0 0 0 2 0.2
Nigeria 21 12 094 8 0.7 2 0.2 2 0.2 4 0.3 4 0.3 1 0.1 21 1.7
Uganda 20 10 626 1 0.1 0 0 0 0 10 0.9 2 0.2 1 0.1 14 1.3
Total 113 72 088 44 0.6 10 0.1 4 0.1 78 1.1 27 0.4 15 0.2 178 2.5
AMR Argentina 14 9 851 14 1.4 25 2.5 8 0.8 10 1.0 5 0.5 14 1.4 76 7.7
Brazil 7 7 093 6 0.8 5 0.7 3 0.4 6 0.8 7 1.0 6 0.8 33 4.6
Ecuador 18 10 124 2 0.2 14 1.4 2 0.2 4 0.4 3 0.3 8 0.8 31 3.1
Mexico 14 13 312 31 2.3 39 2.9 18 1.3 33 2.5 12 0.9 13 1.0 146 11.0
Nicaragua 8 6 488 11 1.7 6 0.9 3 0.5 12 1.8 8 1.2 7 1.1 47 7.2
Paraguay 6 3 626 2 0.6 4 1.1 2 0.6 1 0.3 0 0 1 0.3 10 2.7
Peru 16 15 203 28 1.8 126 8.3 14 0.9 31 2.0 22 1.4 40 2.6 277 18.2
Total 83 65 697 94 1.4 219 3.3 50 0.8 97 1.5 57 0.9 89 1.3 606 9.2
EMR Afghanistan 8 24 478 25 1.0 0 0 2 0.1 5 0.2 4 0.2 2 0.1 38 1.5
Jordan 1 1 197 3 2.5 7 5.8 3 2.5 2 1.7 6 5.0 3 2.5 24 20.0
Lebanon 9 4 118 9 2.2 21 5.1 3 0.7 0 0 1 0.2 3 0.7 37 9.0
OPT 1 975 10 10.2 24 24.6 11 11.3 8 8.2 1 1.0 3 3.1 57 58.5
Pakistan 16 12 889 38 2.9 7 0.5 13 1.0 20 1.6 13 1.0 4 0.3 95 7.4
Qatar 1 4 000 4 1.0 13 3.3 9 2.2 2 0.5 2 0.5 4 1.0 34 8.5
Total 36 48 657 89 1.8 72 1.5 41 0.8 37 0.8 27 0.5 19 0.4 285 5.8
SEAR India 21 30 399 34 1.1 14 0.5 19 0.6 29 0.9 11 0.4 7 0.2 114 3.7
Nepal 8 11 117 8 0 7 3 0.3 0 0 2 0.2 4 0.4 1 0.1 18 1.6
Sri Lanka 14 18 162 22 1.2 88 4.8 10 0.6 75 4.1 32 1.8 24 1.3 251 13.8
Thailand 12 8 976 13 1.5 17 1.9 5 0.6 5 0.6 17 1.9 7 0.8 64 7.1
Total 55 68 654 77 1.1 122 1.8 34 0.5 111 1.6 64 0.9 39 0.6 447 6.5
WPR Cambodia 5 4 691 0 0 2 0.4 0 0 2 0.4 2 0.4 1 0.2 7 1.5
China 21 13 395 3 0.2 22 1.6 2 0.1 23 1.7 14 1.0 0 0 64 4.8
Japan 10 3 566 2 0.6 35 9.8 2 0.6 5 1.4 8 2.2 7 2.0 59 16.5
Mongolia 5 7 385 1 0.1 6 0.8 0 0 5 0.7 2 0.3 2 0.3 16 2.2
Philippines 16 10 711 9 0.8 1 0.1 1 0.1 6 0.6 9 0.8 1 0.1 27 2.5
Viet Nam 15 15 557 3 0.2 5 0.3 2 0.1 3 0.2 2 0.1 2 0.1 17 1.1
Total 72 55 305 18 0.3 71 1.3 7 0.1 44 0.8 37 0.7 13 0.2 190 3.4
Overall Countries 359 310 401 322 1.0 494 1.6 136 0.4 367 1.2 212 0.7 175 0.6 1 706 5.5
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These figures deserve a number of considerations in-
volving accuracy and can very likely be considered un-
derestimates. We excluded stillbirths and multiple
pregnancies from the analysis despite the fact that con-
genital abnormalities generally accounts for a consider-
able proportion of all stillbirths.
In addition, although the WHOMCS was conducted
mainly in secondary and tertiary facilities, and these data
might not be representative of newborn outcomes and
maternal conditions in smaller facilities or in the commu-
nity; it is also likely that some selective ascertainment oc-
curred in relation to maternal pathologic conditions. We
also compared our results for specific malformation cat-
egories with other national sources [20] for countries such
as Japan where we found no substantive differences. The
2012 Annual Report of the International Clearinghouse
for Birth Defects Surveillance and Research reported be-
tween 2 and 3 lip/cleft/palate malformations per 1000
Table 2 The prevalence of newborn with congenital malformations by HDI quartiles per 1000 livebirths














Very High Argentina 14 9 851 14 1.4 25 2.5 8 0.8 10 1.0 5 0.5 14 1.4 76 7.7
Japan 10 3 566 2 0.6 35 9.8 2 0.6 5 1.4 8 2.2 7 2.0 59 16.5
Qatar 1 4 000 4 1.0 13 3.3 9 2.2 2 0.5 2 0.5 4 1.0 34 8.5
Total 25 17 417 20 1.1 73 4.2 10 1.1 17 1.0 15 0.9 25 1.4 169 9.7
High Brazil 7 7 093 6 0.8 5 0.7 3 0.4 6 0.8 7 1.0 6 0.8 33 4.6
Ecuador 18 10 124 2 0.2 14 1.4 2 0.2 4 0.4 3 0.3 8 0.8 31 3.1
Lebanon 9 4 118 9 2.2 21 5.1 3 0.7 0 0 1 0.2 3 0.7 37 9.0
Mexico 14 13 312 31 2.3 39 2.9 18 1.3 33 2.5 12 0.9 13 1.0 146 11.0
Peru 16 15 203 28 1.8 126 8.3 14 0.9 31 2.0 22 1.4 40 2.6 277 18.2
Sri Lanka 14 18 162 22 1.2 88 4.8 10 0.6 75 4.1 32 1.8 24 1.3 251 13.8
Total 78 68 012 98 1.1 293 4.3 50 0.7 149 2.2 77 1.1 94 1.4 775 11.4
Medium India 21 30 399 34 1.1 14 0.5 19 0.6 29 0.9 11 0.4 7 0.2 114 3.7
Jordan 1 1 197 3 2.5 7 5.8 3 2.5 2 1.7 6 5.0 3 2.5 24 20.0
Cambodia 5 4 691 0 0 2 0.4 0 0 2 0.4 2 0.4 1 0.2 7 1.5
China 21 13 395 3 0.2 22 1.6 2 0.1 23 1.7 14 1.0 0 0 64 4.8
Mongolia 5 7 385 1 0.1 6 0.8 0 0 5 0.7 2 0.3 2 0.3 16 2.2
Nicaragua 8 6 488 11 1.7 6 0.9 3 0.5 12 1.8 8 1.2 7 1.1 47 7.2
OPT 1 975 10 10.2 24 24.6 11 11.3 8 8.2 1 1.0 3 3.1 57 58.5
Paraguay 6 3 626 2 0.6 4 1.1 2 0.6 1 0.3 0 0 1 0.3 10 2.7
Philippines 16 10 711 9 0.8 1 0.1 1 0.1 6 0.6 9 0.8 1 0.1 27 2.5
Thailand 12 8 976 13 1.5 17 1.9 5 0.6 5 0.6 17 1.9 7 0.8 64 7.1
Viet Nam 15 15 557 3 0.2 5 0.3 2 0.1 3 0.2 2 0.1 2 0.1 17 1.1
Total 111 103 400 89 1.0 108 1.0 48 0.5 96 0.9 72 0.7 34 0.3 447 4.3
Low Afghanistan 8 24 478 25 1.0 0 0 2 0.1 5 0.2 4 0.2 2 0.1 38 1.5
Angola 20 10 072 0 0 1 0.1 0 0 1 0.1 1 0.1 1 0.1 4 0.4
DR Congo 21 8 525 5 0.6 1 0.1 0 0 6 0.7 2 0.2 1 0.1 15 1.7
Kenya 20 20 057 30 1.5 6 0.3 2 0.1 55 2.7 18 0.9 11 0.5 122 6.1
Nepal 8 11 117 8 0.7 3 0.3 0 0 2 0.2 4 0.4 1 0.1 18 1.6
Niger 11 10 714 0 0 0 0 0 0 2 0.2 0 0 0 0 2 0.2
Nigeria 21 12 094 8 0.7 2 0.2 2 0.2 4 0.3 4 0.3 1 0.1 21 1.7
Pakistan 16 12 889 38 2.9 7 0.5 13 1.0 20 1.6 13 1.0 4 0.3 95 7.4
Uganda 20 10 626 1 0.1 0 0 0 0 10 0.9 2 0.2 1 0.1 14 1.3
Total 145 121 572 115 1.2 20 0.2 19 0.2 105 0.9 48 0.4 22 0.2 329 2.7
Overall Countries 359 310 401 322 1.0 494 1.6 136 0.4 367 1.2 212 0.7 175 0.6 1 706 5.5
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total births (livebirths and stillbirths) for Japan compared
to 2.2 per 1000 livebirths of the WHOMCS.
On the other hand the true rate of cardiovascular de-
fects is around 1 %, known from numerous studies [25,
26], whilst in this study the overall rate is only 0.16 %,
again indicating a certain level of under ascertainment.
Even though our dataset does not provide specific in-
formation on consanguinity, high frequency of congeni-
tal disorders in countries of the Eastern Mediterranean
Region is largely regarded as due to consanguineous
marriage, 25–70 % of unions involve related family
members: parental consanguinity increases the birth
prevalence of autosomal recessive birth defects and the
risk of neonatal and childhood death, intellectual disabil-
ity and serious birth defects is almost doubled for first
cousin unions [27–30].
Our analysis revealed around four times increased odds
of “renal”, “limb” and “lip/cleft/palate” malformations
Table 3 Maternal characteristics in all Congenital Malformations groups
All women Neural tube/Central
nervous system
Cardiac Renal Limb Lip/Cleft/Palate Chromosomal
N n (%) χ2 n (%) χ2 n (%) χ2 n (%) χ2 n (%) χ2 n (%) χ2
Maternal age (years) 0.9 <0.01 0.07 0.5 0.9 <0.01
<20 31 259 31 (9.8) 39 (8.2) 7 (5.2) 42 (11.8) 18 (8.5) 14 (8.1)
20–35 244 425 238 (75.5) 340 (71.4) 111 (82.8) 278 (78.5) 162 (76.8) 91 (52.9)
>35 25 583 46 (14.7) 97 (20.4) 16 (12.0) 34 (9.7) 31 (14.7) 67 (39.0)
Missing 868
Marital Status 0.6 0.09 0.3 0.7 0.09 0.5
Single 30 583 35 (11.2) 32 (6.8) 10 (7.5) 38 (10.8) 12 (5.8) 15 (8.8)
Married 268 051 278 (88.8) 440 (93.2) 124 (92.5) 314 (89.2) 194 (94.2) 155 (91.2)
Missing 3 501
Education (years) 0.4 <0.01 0.9 <0.01 <0.01 0.8
<5 54 693 55 (18.5) 13 (3.2) 13 (10.1) 38 (12.4) 16 (8.6) 13 (8.8)
5–8 62 952 68 (23.0) 60 (14.8) 22 (17.0) 70 (22.9) 41 (21.8) 24 (16.3)
9–11 71 550 88 (29.7) 166 (41.0) 40 (31.0) 105 (34.3) 77 (40.9) 53 (36.1)
>11 88 274 85 (28.8) 165 (41.0) 54 (41.9) 93 (30.4) 54 (28.7) 57 (38.8)
Missing 24 666
N previous births 0.3 0.2 0.5 0.4 0.2 <0.01
0 128 479 123 (39.0) 208 (43.6) 52 (38.5) 161 (45.2) 76 (36.2) 58 (33.5)
1–2 125 401 135 (42.9) 216 (45.3) 63 (46.7) 156 (43.8) 97 (46.2) 78 (45.1)
>2 47 672 57 (18.1) 53 (11.1) 20 (14.8) 39 (11.0) 37 (17.6) 37 (21.4)
Missing 583
Table 4 Crude and adjusted Odds Ratio of pregnancy hypertensive disorders and congenital malformations





















4.2 (1.7–10.2) 2.3 (0.9–5∙.9) 2.0 (1.2–3.6) 1.5 (0.8–2.7) - - 9.9 (3.1–31.0) 4.3 (1.3–14.4)
Cardiac 2.8 (1∙.–6.7) 1.9 (0.8–4.7) 3.3 (2.3–4.8) 2.3 (1.6–3.5) 0.8 (0.1–5.9) - 4.3 (1.1–17.5) 2.3 (0.5–9.6)
Renal 8.0 (2.9–21.7) 3.7 (1.3–10.7) 2.6 (1.2–5.6) 1.8 (0.8–3.8) - - 23.6 (7.4–74.4) 8.7 (2.5–30.2)
Limb 4.5 (2.0–10.1) 3.9 (1.7–9.0) 2.0 (1.1–3.4) 1.7 (0.9–3.1) - - 8.8 (2.8–27.6) 7.1 (2.1–23.5)
Lip/Cleft/Palate 5.1 (1.9–13.6) 4.2 (1.5–11.6) 1.4 (0.6–3.2) 1.3 (0.6–3.0) 1.9 (0.3–13.4) 2.8 (0.4–20.3) 9.9 (2.4–39.9) 8.2 (2.0–34.3)
Chromosomal 3.1 (0.7–12.3) 0.9 (0.1–6.6) 1.7 (0.8–3.9) 0.8 (0.3–2.2) - - 6.0 (0.8–42.9) 0.8 (0.2–4.1)
aOR Adjusted for Age, Education, Previous births and Marital Status with country and facility as random mixed effect variable
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associated with chronic maternal hypertension (Table 4);
these associations were further increased in the condition
of chronic hypertension with superimposed preeclampsia
where adjusted odds ratio ranged from 7.1 for “limb” to
8.7 for “renal” malformations. The analysis also showed
2.3 and 1.6 times increased odd of respectively “cardiac”
and “other” malformations due to preeclampsia as well as
4.3 times increased odd of “neural tube/central nervous
system” malformations due to chronic hypertension with
superimposed preeclampsia.
Since no correlation was detected between WHO re-
gions with respect to registered malformations risk and
registered hypertension risk the association between the
two variables is likely to be true.
Pregnant women with chronic hypertension presumably
had this condition prior to conception and throughout preg-
nancy; therefore, during the critical period for organogenesis
where major congenital abnormalities can develop, it is im-
portant to remark how a “dose/effect relationship” manifests
when considering the increased risk of renal, limb and lip/
cleft/palate malformations due to the chronic hypertension
with superimposed preeclampsia when compared with the
significant associations of the same defects with only
chronic hypertension. This effect has also been shown in a
recent large case–control study in US although this study
did not find statistically significant association between
hypertensive disorders and these specific birth defects [31].
The association between chronic hypertension with
superimposed preeclampsia with renal dysgenesis has
been reported by a previous case–control study [12]; how-
ever we should address the lack of information in our
datasets concerning use of angiotensin-converting enzyme
inhibitors and angiotensin II receptor inhibitors/antago-
nists which are contraindicated in pregnant women due to
their teratogenicity [32].
Other studies found similar effects of beta-blockers
[33] and suggested that the general effect of anti-
hypertensives could be an effect of drug-induced fetal
hypotension or an effect of the underlying disease [34].
It is difficult to determine what possible mechanisms
may have led to the association of chronic hypertension
with higher rates of limb and lip/cleft/palate defects.
The lack of association between preeclampsia and
most of congenital malformations can be explained by
the onset of this hypertensive disorder after the first tri-
mester; nevertheless the association of preeclampsia with
cardiac defects might be explained in line with a com-
mon genetic predisposition for angiogenic/anti-angio-
genic imbalance in maternal and fetal blood [35].
It also not obvious to argue a causal effect of chronic
hypertension with superimposed preeclampsia on the in-
surgence of neural tube defects; however a recent article
put the evidence on the effect of the folic acid supple-
mentation, well known for protecting from the risk of
neural tube/spina bifida [36, 37], in reducing the risk of
gestational hypertension and preeclampsia [38] suggest-
ing again a common pathway for the two conditions.
Strengths of this analysis include the large and multi-
country dataset for the purpose of exploring the inci-
dence of congenital malformation and its association
with hypertensive disorders of pregnancy. Consistency in
study methodology and definitions across facilities and
countries enhance comparability. In addition, the large
sample size allows for stratification by type of hyperten-
sive disorder providing more clinical relevance.
This analysis presents several limitations. In the
WHOMCS, a specific ascertainment of congenital mal-
formations was not carried out and only broader groups
of congenital malformations were included. Hence we
were not able to consider the specific birth defect
categories that may be associated with hypertensive
disorders. In this regard, we were unable to assess asso-
ciations between specific congenital malformations (such
as esophageal atresia and hypospadias) and hypertensive
Table 5 Sensitivity Analysis: Crude and adjusted Odds Ratio of pregnancy hypertensive disorders and congenital malformations
excluding AFR countries





















4.4 (1.8–10.7) 2.4 (0.9–6.1) 1.3 (0.6–2.7) 1.0 (0.5–2.1) - - 9.7 (3.1–30.5) 4.2 (1.3–14.1)
Cardiac 2.6 (1.1–6.2) 1.9 (0.8–4.8) 3.1 (2.2–4.5) 2.4 (1.6–3.6) 1.2 (0.2–8.5) - 3.7 (0.9–15.1) 2.3 (0.5–9.6)
Renal 7.4 (2.7–20.2) 3.7 (1.3–10.7) 2.5 (1.1–5.3) 1.7 (0.8–3.8) - - 20.5 (6.5–64.9) 8.4 (2.4–29.5)
Limb 5.1 (2.3–11.6) 4.0 (1.7–9.5) 1.6 (0.8–3.0) 1.3 (0.7–2.6) - - 9.4 (3.0–29.4) 7.1 (2.1–23.5)
Lip/Cleft/Palate 5.3 (1.9–14.2) 4.4 (1.6–12.0) 1.5 (0.6–3.3) 1.4 (0.6–3.3) 3.0 (0.4–21.7) 2.9 (0.4–20.4) 9.6 (2.4–38.8) 7.7 (1.8–31.9)
Chromosomal 3.0 (0.7–12.1) 0.9 (0.1–6.7) 1.4 (0.6–3.4) 0.8 (0.3–2.3) - - 5.5 (0.8–39.2) 0.7 (0.3–4.3)
aOR Adjusted for Age, Education, Previous births and Marital Status with country and facility as random mixed effect variable
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disorders that have been identified in other studies [11–
14]. Another limitation concerns the outcome variable,
congenital malformations, being ascertained at birth or
immediately after birth. Some birth defects like several
cardiac lesions appear late (there may be delayed appear-
ance/capture even up to 5 years) [17].
For the exposure variables (“Eclampsia”, “Pre-eclampsia”
and “Chronic Hypertension”) time of onset or duration of
exposure is not specified in WHOMCS database. This is
important since many congenital malformations occur be-
fore 8 weeks of gestation and risk lies in pre-conception
period. In addition, the WHOMCS did not collect data on
antihypertensive medication exposure and other risk fac-
tors associated with a number of specific birth defects.
Many other major risk factors (eg. diabetes, smoking,
obesity, alcohol use) were not available to give adjusted
OR. ORs were calculated only for age, education, previous
births and marital Status.
Disparities in the ascertainment of congenital malfor-
mations in high and low HDI countries is clearly appar-
ent with very high and high HDI countries reporting a
majority of congenital malformations even with lesser
number of live births.
Conclusions
To our knowledge this is one of the few analyses reporting
estimate the prevalence of congenital malformation in fa-
cilities in middle and low income countries where more
than 90 % of all infants with a serious birth defect are born
and where many of them will die young because of lack of
adequate health care services [39]. A concerted effort to
start a systematic collection, analysis and dissemination of
data on congenital malformation is crucial for the years to
come when the burden of disease will increase with the
steady proportional decrease of post neonatal mortality.
As a step towards this objective, in 2014 WHO published
a manual intended to serve as a tool for the development,
implementation and ongoing improvement of congenital
anomalies surveillance programmes, particularly for coun-
tries with limited resources [40].
In view of findings and characteristics of our study we
also suggest additional research on associations and pos-
sible common pathogenesis pathways in maternal hyper-
tensive disorders and congenital defects, given their
roles in maternal and child morbidity and mortality.
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